ライフサイエンスコーパス: ADEM

1 ADEM/MDEM patients were more likely to have blood leucoc

2 The mean follow-up for the 35 ADEM/MDEM patients was 5.78 years (range 1.0-15.4 years)

3 ed a risk difference (excess risk) of TM and ADEM for each vaccine.

4 We identified all cases of TM and ADEM in the Vaccine Safety Datalink population.

5 Defining ADEM and distinguishing it from multiple sclerosis early

6 ), and acute disseminated encephalomyelitis (ADEM) (8%).

7 s with acute disseminated encephalomyelitis (ADEM) associated with Group A beta hemolytic streptococc

8 Acute disseminated encephalomyelitis (ADEM) is a demyelinating disorder most common in childho

9 th non-acute disseminated encephalomyelitis (ADEM) presentations, as did the 2005 McDonald criteria.

10 s with acute disseminated encephalomyelitis (ADEM) selectively bound the folded MOG tetramer, whereas

11 TM) or acute disseminated encephalomyelitis (ADEM), but the evidence for a causal association is inco

12 luding acute disseminated encephalomyelitis (ADEM), one episode of transverse myelitis or optic neuri

13 8 with acute disseminated encephalomyelitis (ADEM), seven with multiphasic disseminated encephalomyel

14 o with acute disseminated encephalomyelitis (ADEM), two with ON, one with transverse myelitis (TM) an

15 s like acute disseminated encephalomyelitis (ADEM).

16 with acute disseminating encephalomyelitis (ADEM), but the clinical and neuroradiological characteri

17 For ADEM, it is speculated that a preceding infection is the

18 For ADEM, there was no statistically significant increased r

19 at MOG is a more prominent target antigen in ADEM than MS.

20 By contrast, in ADEM/MDEM there was absolute and relative periventricula

21 ollowing findings were more commonly seen in ADEM/MDEM presentation compared with the multiple sclero

22 an advection-diffusion equation with memory (ADEM) whose parameters are obtained from a mean group ve

23 In younger children with a non-ADEM presentation, PPV of the 2010 criteria was only 55%

24 red to 18% of patients with nonstreptococcal ADEM.

25 There was a possible association of ADEM with Tdap vaccine, but the excess risk is not likel

26 is not likely to be more than 1.16 cases of ADEM per million vaccines administered.

27 ine doses, only 7 cases of TM and 8 cases of ADEM were vaccinated during the primary exposure window

28 te aimed at differential characterization of ADEM and childhood multiple sclerosis have been retrospe

29 not suited for application in the context of ADEM-like presentations.

30 ill be required to arrive at a definition of ADEM so as to distinguish it from childhood multiple scl

31 These differences in the presentation of ADEM/MDEM compared with multiple sclerosis may help in t

32 utoantibodies were identified in a subset of ADEM but only rarely in adult-onset MS cases, indicating

33 nization and subsequent development of TM or ADEM.

34 ies, outcome and MOG status of 33 paediatric ADEM prospectively studied were reviewed.

35 nificantly elevated in the poststreptococcal ADEM group compared with neurological controls.

36 ia in 80% of patients with poststreptococcal ADEM, compared to 18% of patients with nonstreptococcal

37 ABGA in the patients with poststreptococcal ADEM.

38 The outcome in the ADEM patients was mixed; 57% of patients made a complete

39 Seizures occurred only in the ADEM/MDEM group (17 versus 0%, not significant).

40 resolution in 90% and no new lesions in the ADEM/MDEM group.

41 The presentation findings of the ADEM/MDEM group were compared with those of the multiple

42 s ratio for Tdap exposure 5-28 days prior to ADEM onset was 15.8 (95% confidence interval [CI], 1.2-4

43 Some children with ADEM develop additional temporally remote episodes of de

44 None of the 50 children with ADEM met clinical criteria for MS, but 10 met 2010 and 4

45 -1:20 480) were detected in 19 children with ADEM.

46 Patients with ADEM with MOG antibodies in our cohort had a uniform MRI

47 AR)-Ab was found in two; one presenting with ADEM and one with ON.

48 were positive in three; one presenting with ADEM, one with ON and one with CIS.